Strategic partnerships Diasorin’s aggressive distribution moves with McKesson for Liaison Nes point-of-care systems indicate strong appetite for channel expansion and regional coverage. Leverage co-selling and distributor-aligned campaigns to accelerate reach in clinical diagnostics and point-of-care segments.

Next-gen assays Recent CE-marked launches like LIAISON QuantiFERON-TB Gold Plus II and Simplexa C. auris Direct kit show a focus on high-throughput, rapid diagnostics. Target labs prioritizing speed, throughput, and expanded test menus with compatible instrumentation and service packages.

Diverse markets Luminex/DiaSorin serves clinical diagnostics, pharma discovery, biomedical research, genomics/proteomics, and food safety. Position bundled solutions and cross-sell across research, clinical, and industry QC customers to maximize addressable spend with integrated platforms.

Growth through acquisitions Historical integration of Luminex assets by DiaSorin and ongoing portfolio optimization suggest a readiness to rationalize or expand SKUs. Propose targeted acquisitions-adjacent offerings, migration pathways, and upgrade programs to capture existing customers migrating from legacy systems.

Financial stability Revenue banding of 500M–1B with a sizable employee base signals solid scale and investment capacity. Present premium service contracts, supported maintenance, and long-term supplier financing to enterprise buyers seeking reliable total-cost-of-ownership benefits.